Details for: XALKORI
Company: PFIZER CANADA ULC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02384256 | XALKORI | CRIZOTINIB | 200 MG | CAPSULE | ORAL |
| 02384264 | XALKORI | CRIZOTINIB | 250 MG | CAPSULE | ORAL |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Summary Safety Review - XALKORI (crizotinib) - Assessing the potential risk of developing a hole in the bowel (gastrointestinal perforation)
Regulatory Decision Summary
Summary Safety Review - XALKORI (crizotinib) - Assessing the potential risk of developing a hole in the bowel (gastrointestinal perforation)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.